OK got it, I would have thought that Eylea biosimilars are not bad news for OPT or its commercialization. However, with the share price down, I thought there might be a negative impact, and I was concerned that I failed to draw a line between the dots in your posting.
Anyway, in many respects, a successful Phase 3 trial, even with lower than expected sales, is still going to be a huge win for holders at 62 cents.
It was my understanding that there is nothing in Phase 3 pipeline that would be a competitor to Sozinibercept.
OK got it , I would have thought that Eylea biosimilars are not...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $403.8M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.8¢ | 36.0¢ | $449.8K | 1.213M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 75447 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 64363 | 12 |
View Market Depth
| Last trade - 15.26pm 11/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |